吉西他滨和多西他赛作为原发部位不明癌患者的一线化疗方案。
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
作者信息
Pouessel Damien, Culine Stéphane, Becht Catherine, Ychou Marc, Romieu Gilles, Fabbro Michel, Cupissol Didier, Pinguet Frédéric
机构信息
Department of Medical Oncology, Centre Régional de Lutte contre le Cancer Val d'Aurelle, Montpellier, France.
出版信息
Cancer. 2004 Mar 15;100(6):1257-61. doi: 10.1002/cncr.20100.
BACKGROUND
The current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site.
METHODS
Patients were to receive intravenous gemcitabine at a dose of 1000 mg/m2 over 30 minutes on Days 1 and 8 and docetaxel at a dose of 75 mg/m2 over 1 hour on Day 8 in an outpatient setting. The schedule was repeated every 3 weeks for a maximum of 6 cycles.
RESULTS
Thirty-five patients were assessable for response and survival. One complete and 13 partial responses were observed. The overall response rate was 40% (95% confidence interval, 28-52%). The median time to disease progression was 2 months (range, 1-4 months). The median overall survival time was 10 months (range, 0-32 months). Toxicity was reported to be manageable.
CONCLUSIONS
The combination of gemcitabine and docetaxel was found to be active in patients with carcinomas of an unknown primary site. However, the overall outcome of these patients remains poor and novel treatment approaches are required.
背景
本研究旨在评估以吉西他滨和多西他赛联合组成的非顺铂化疗方案作为一线化疗方案，用于治疗原发部位不明癌患者的疗效和毒性。
方法
患者在门诊接受治疗，第1天和第8天静脉输注吉西他滨，剂量为1000mg/m²，输注时间30分钟；第8天静脉输注多西他赛，剂量为75mg/m²，输注时间1小时。每3周重复一次该治疗方案，最多进行6个周期。
结果
35例患者可评估疗效和生存情况。观察到1例完全缓解和13例部分缓解。总缓解率为40%（95%置信区间，28 - 52%）。疾病进展的中位时间为2个月（范围，1 - 4个月）。中位总生存时间为10个月（范围，0 - 32个月）。据报道毒性可控制。
结论
发现吉西他滨和多西他赛联合方案对原发部位不明癌患者有活性。然而，这些患者的总体预后仍然较差，需要新的治疗方法。
Zotero 插件